• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Lunit, AstraZeneca Partner to Develop AI-Powered Pathology Tools for Faster Lung Cancer Diagnostics

by Fred Pennic 11/18/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Advancing precision in lung cancer diagnostics: Lunit’s collaboration with AstraZeneca aims to transform the speed and accuracy of detecting actionable mutations in NSCLC. (Courtesy of Lunit)

What You Should Know: 

– Lunit, a provider of AI solutions for cancer diagnostics and therapeutics, has announced a strategic collaboration with AstraZeneca, a global pharmaceutical company, to develop AI-powered digital pathology solutions. 

– The partnership aims to improve cancer treatment by leveraging AI to analyze tissue samples and predict the likelihood of specific genetic mutations.

Focusing on Lung Cancer Treatment with AI

The collaboration will initially focus on developing Lunit SCOPE Genotype Predictor, an AI-powered tool that analyzes images of stained tissue samples to predict the likelihood of non-small cell lung cancer (NSCLC) driver mutations, such as those in the Epidermal Growth Factor Receptor (EGFR) gene.

Identifying these mutations is critical for determining the most effective treatment strategies for NSCLC patients. However, traditional genomic testing can be time-consuming and resource-intensive. Lunit SCOPE Genotype Predictor offers a faster and more cost-effective approach by:

  • Analyzing H&E Slides: Predicts the likelihood of EGFR and other NSCLC driver mutations directly from standard H&E-stained tissue slides.
  • Prioritizing Molecular Testing: Helps prioritize patients for molecular testing based on the AI’s prediction, potentially speeding up the diagnosis and treatment process.
  • Informing Treatment Decisions: Provides valuable insights to guide treatment decisions and personalize cancer care.

Empowering Healthcare Practitioners

By providing healthcare practitioners with cutting-edge AI tools, Lunit and AstraZeneca are empowering them to:

  • Optimize diagnostic workflows: Streamline the process of identifying patients with specific genetic mutations.
  • Prioritize molecular testing: Ensure that patients receive timely and appropriate testing.
  • Personalize cancer treatment: Select the most effective therapies based on individual genetic profiles.

“We are excited to partner with AstraZeneca, a leader in oncology therapeutics, to develop and evaluate this groundbreaking technology,” said Brandon Suh, CEO of Lunit. “The integration of Lunit SCOPE Genotype Predictor as a screening test into pathology workflows promises to improve the opportunity for patients to benefit from appropriate targeted therapy, ultimately improving patient outcomes and streamlining the treatment planning process.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |